A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

pay.thelady61 shared this article with you from Inoreader A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder Via ClinicalTrials.gov: HEAD AND NECK | Open Studies | updated in the last 14 days Condition:   Urinary Bladder Neoplasms Interventions:   Drug: Cetrelimab;   Drug: TAR-200;   Drug: Cisplatin;   Drug: Gemcitabine;   Radiation: Conventional radiation therapy;   Radiation: Hypo-fractioned radiation therapy Sponsor:   Janssen Research & Development, LLC Not yet recruiting View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.